tranexamic acid and Brain Hemorrhage, Cerebral studies

Research Excerpts

Excerpt	Relevance	Reference
" Tranexamic acid (TXA) is an antifibrinolytic drug potentially limiting hematoma expansion."	9.69	Tranexamic Acid for Intracerebral Hemorrhage in Patients on Non-Vitamin K Antagonist Oral Anticoagulants (TICH-NOAC): A Multicenter, Randomized, Placebo-Controlled, Phase 2 Trial. ( Barinka, F; Baumgartner, P; Bonati, LH; De Marchis, GM; Engelter, ST; Fischer, U; Gensicke, H; Guzman, R; Kägi, G; Karwacki, GM; Lyrer, PA; Maurer, M; Nedeltchev, K; Nickel, CH; Peters, N; Polymeris, AA; Schaedelin, S; Seiffge, DJ; Siepen, BM; Sprigg, N; Stippich, C; Thilemann, S; Traenka, C; Tsakiris, DA; Vehoff, J; Wagner, B; Wegener, S; Z'Graggen, WJ, 2023)
"This prospective nested magnetic resonance imaging (MRI) substudy of a randomized clinical trial (RCT) recruited participants from the multicenter, double-blind, placebo-controlled, phase 3 RCT (Tranexamic Acid for Hyperacute Primary Intracerebral Hemorrhage [TICH-2]) from July 1, 2015, to September 30, 2017, and conducted follow-up to 90 days after participants were randomized to either the tranexamic acid or placebo group."	9.51	Effect of Tranexamic Acid Administration on Remote Cerebral Ischemic Lesions in Acute Spontaneous Intracerebral Hemorrhage: A Substudy of a Randomized Clinical Trial. ( Al-Shahi Salman, R; Bath, PM; Casado, AM; Dineen, RA; England, TJ; Gallagher, R; Law, ZK; Morgan, PS; Pszczolkowski, S; Roberts, I; Sprigg, N; Swienton, D; Werring, DJ; Woodhouse, LJ, 2022)
"TICH-2 trial (Tranexamic Acid for Hyperacute Primary Intracerebral Haemorrhage) was a randomized, placebo-controlled clinical trial recruiting acutely hospitalized participants with intracerebral hemorrhage within 8 hours after symptom onset."	9.41	Tranexamic Acid for Prevention of Hematoma Expansion in Intracerebral Hemorrhage Patients With or Without Spot Sign. ( Bath, PM; Christensen, H; Christensen, LM; Dineen, RA; Flaherty, K; Gluud, C; Jakobsen, JC; Law, Z; Overgaard, K; Ovesen, C; Rasmussen, RS; Sprigg, N; Steiner, T, 2021)
"Treatment with tranexamic acid could reduce hematoma expansion in intracerebral hemorrhage, and the treatment was safe with no increase in thromboembolic complications."	9.41	Tranexamic acid in intracerebral hemorrhage: a meta-analysis. ( Ling, L; Yu, Z, 2023)
"This pragmatic trial is assessing efficacy of tranexamic acid after spontaneous intracerebral hemorrhage."	9.22	Intravenous tranexamic acid for hyperacute primary intracerebral hemorrhage: Protocol for a randomized, placebo-controlled trial. ( Al-Shahi Salman, R; Bath, P; Bereczki, D; Beredzie, M; Christensen, H; Ciccone, A; Collins, R; Czlonkowska, A; Dineen, R; Duley, L; Egea-Guerrero, JJ; England, T; Laska, AC; Law, ZK; Ozturk, S; Pocock, S; Roberts, I; Robinson, T; Robson, K; Roffe, C; Seiffge, D; Sprigg, N; Werring, D; Whynes, D, 2016)
"The objective of this systematic review was to evaluate the efficacy and safety of tranexamic acid in patients with spontaneous intracerebral hemorrhage."	9.12	Tranexamic Acid for Adult Patients with Spontaneous Intracerebral Hemorrhage: A Systematic Review with Meta-analysis. ( Ma, L; Song, J; Wang, X; You, C, 2021)
"Treatment with tranexamic acid could reduce rebleeding and hematoma expansion in cerebral hemorrhage without an increase in single ischemic adverse events, but it could increase the risk of combined ischemic events; however, the lack of improvement in mortality and the poor functional outcomes limit the value of clinical application."	9.01	Tranexamic Acid in Cerebral Hemorrhage: A Meta-Analysis and Systematic Review. ( Chen, X; He, Z; Hu, W; Song, Z; Xin, Y; Zhao, Y, 2019)
"Tranexamic acid might be beneficial for cerebral hemorrhage."	8.98	Influence of tranexamic acid on cerebral hemorrhage: A meta-analysis of randomized controlled trials. ( Huang, B; Xu, J; Xu, Q; Ye, R, 2018)
"prothrombin complex concentrate and fresh-frozen plasma effectively prevent hematoma growth in murine warfarin-associated intracerebral hemorrhage, whereas Factor VIIa was less effective."	7.77	Comparative effectiveness of hemostatic therapy in experimental warfarin-associated intracerebral hemorrhage. ( Heiland, S; Illanes, S; Schwarting, S; Veltkamp, R; Zhou, W, 2011)
"Rationale Acute intracerebral hemorrhage inflicts a high-economic and -health burden."	6.84	Tranexamic acid for acute intracerebral hemorrhage growth predicted by spot sign trial: Rationale and design. ( Li, N; Liu, D; Liu, L; Meng, X; Nie, X; Tan, Y; Wang, Y; Zhao, X, 2017)
"Spontaneous intracerebral hemorrhage (ICH) can be devastating, particularly if hematoma expansion (HE) occurs."	6.79	Tranexamic acid for spontaneous intracerebral hemorrhage: a randomized controlled pilot trial (ISRCTN50867461). ( Bath, PM; Dineen, RA; Kwong, Y; Renton, CJ; Sprigg, N, 2014)
"Tranexamic acid (TXA) is an antifibrinolytic agent, which has shown an effect on reducing blood loss in many diseases."	6.72	Tranexamic Acid Inhibits Hematoma Expansion in Intracerebral Hemorrhage and Traumatic Brain Injury. Does Blood Pressure Play a Potential Role? A Meta-Analysis from Randmized Controlled Trials. ( Chen, Z; Gao, B; Rong, X; Wang, Z; Xue, T; Yang, Y, 2021)
" Tranexamic acid (TXA) is an antifibrinolytic drug potentially limiting hematoma expansion."	5.69	Tranexamic Acid for Intracerebral Hemorrhage in Patients on Non-Vitamin K Antagonist Oral Anticoagulants (TICH-NOAC): A Multicenter, Randomized, Placebo-Controlled, Phase 2 Trial. ( Barinka, F; Baumgartner, P; Bonati, LH; De Marchis, GM; Engelter, ST; Fischer, U; Gensicke, H; Guzman, R; Kägi, G; Karwacki, GM; Lyrer, PA; Maurer, M; Nedeltchev, K; Nickel, CH; Peters, N; Polymeris, AA; Schaedelin, S; Seiffge, DJ; Siepen, BM; Sprigg, N; Stippich, C; Thilemann, S; Traenka, C; Tsakiris, DA; Vehoff, J; Wagner, B; Wegener, S; Z'Graggen, WJ, 2023)
"Stopping intracerebral haemorrhage with tranexamic acid for hyperacute onset presentation including mobile stroke units (STOP-MSU) is a phase II double-blind, randomised, placebo-controlled, multicentre, international investigator-led clinical trial, conducted within the estimand statistical framework."	5.51	Tranexamic acid for intracerebral haemorrhage within 2 hours of onset: protocol of a phase II randomised placebo-controlled double-blind multicentre trial. ( Brown, H; Campbell, BCV; Cheung, A; Cho, DY; Choi, P; Churilov, L; Clissold, B; Cloud, GC; Dang, DP; Davis, SM; Donnan, GA; Grimley, R; Hsu, CY; Jeng, JS; Kleinig, T; Levi, C; Ma, H; Mahawish, K; Meretoja, A; Mitchell, PJ; Nguyen, HT; Parsons, MW; Phuong, NTM; Ranta, A; Sanders, L; Shah, D; Sharma, G; Spratt, N; Ton, MD; Wang, HK; Worthington, J; Wu, T; Yan, B; Yassi, N; Yogendrakumar, V; Zhao, H, 2022)
"This prospective nested magnetic resonance imaging (MRI) substudy of a randomized clinical trial (RCT) recruited participants from the multicenter, double-blind, placebo-controlled, phase 3 RCT (Tranexamic Acid for Hyperacute Primary Intracerebral Hemorrhage [TICH-2]) from July 1, 2015, to September 30, 2017, and conducted follow-up to 90 days after participants were randomized to either the tranexamic acid or placebo group."	5.51	Effect of Tranexamic Acid Administration on Remote Cerebral Ischemic Lesions in Acute Spontaneous Intracerebral Hemorrhage: A Substudy of a Randomized Clinical Trial. ( Al-Shahi Salman, R; Bath, PM; Casado, AM; Dineen, RA; England, TJ; Gallagher, R; Law, ZK; Morgan, PS; Pszczolkowski, S; Roberts, I; Sprigg, N; Swienton, D; Werring, DJ; Woodhouse, LJ, 2022)
"To determine the effect of Intravenous Tranexamic Acid (TXA) on traumatic intracerebral hemorrhage."	5.41	Effect of Intravenous Tranexamic Acid on Intracerebral Brain Hemorrhage in Traumatic Brain Injury. ( Farrahi, P; Marandi, HJ; Rasras, S; Safari, H; Zeinali, M, 2021)
"TICH-2 trial (Tranexamic Acid for Hyperacute Primary Intracerebral Haemorrhage) was a randomized, placebo-controlled clinical trial recruiting acutely hospitalized participants with intracerebral hemorrhage within 8 hours after symptom onset."	5.41	Tranexamic Acid for Prevention of Hematoma Expansion in Intracerebral Hemorrhage Patients With or Without Spot Sign. ( Bath, PM; Christensen, H; Christensen, LM; Dineen, RA; Flaherty, K; Gluud, C; Jakobsen, JC; Law, Z; Overgaard, K; Ovesen, C; Rasmussen, RS; Sprigg, N; Steiner, T, 2021)
"Treatment with tranexamic acid could reduce hematoma expansion in intracerebral hemorrhage, and the treatment was safe with no increase in thromboembolic complications."	5.41	Tranexamic acid in intracerebral hemorrhage: a meta-analysis. ( Ling, L; Yu, Z, 2023)
"Exclusion criteria were ICH secondary to anticoagulation, thrombolysis, trauma or a known underlying structural abnormality; patients for whom tranexamic acid was thought to be contraindicated; prestroke dependence (i."	5.30	Tranexamic acid to improve functional status in adults with spontaneous intracerebral haemorrhage: the TICH-2 RCT. ( Al-Shahi Salman, R; Appleton, JP; Bath, PM; Bereczki, D; Beridze, M; Ciccone, A; Collins, R; Dineen, RA; Duley, L; Egea-Guerrero, JJ; England, TJ; Flaherty, K; Karlinski, M; Krishnan, K; Laska, AC; Law, ZK; Ovesen, C; Ozturk, S; Peters, N; Pocock, SJ; Roberts, I; Robinson, TG; Roffe, C; Scutt, P; Sprigg, N; Thanabalan, J; Werring, D; Whynes, D; Woodhouse, L, 2019)
"This pragmatic trial is assessing efficacy of tranexamic acid after spontaneous intracerebral hemorrhage."	5.22	Intravenous tranexamic acid for hyperacute primary intracerebral hemorrhage: Protocol for a randomized, placebo-controlled trial. ( Al-Shahi Salman, R; Bath, P; Bereczki, D; Beredzie, M; Christensen, H; Ciccone, A; Collins, R; Czlonkowska, A; Dineen, R; Duley, L; Egea-Guerrero, JJ; England, T; Laska, AC; Law, ZK; Ozturk, S; Pocock, S; Roberts, I; Robinson, T; Robson, K; Roffe, C; Seiffge, D; Sprigg, N; Werring, D; Whynes, D, 2016)
"This is the first trial to evaluate the efficacy of tranexamic acid in intracerebral hemorrhage patients selected based on an imaging biomarker of high likelihood of hematoma growth."	5.19	The spot sign and tranexamic acid on preventing ICH growth--AUStralasia Trial (STOP-AUST): protocol of a phase II randomized, placebo-controlled, double-blind, multicenter trial. ( Anderson, CS; Aviv, RI; Barras, C; Bladin, C; Campbell, BC; Churilov, L; Davis, SM; Delcourt, C; Donnan, GA; Jannes, J; Kleinig, T; Lee, A; Levi, C; Mahant, N; Markus, R; Meretoja, A; Mitchell, P; Nandurkar, H; Parsons, MW; Rupasinghe, J; Spratt, NJ; Sturm, J; Wijeratne, T; Yan, B; Yassi, N; Zavala, J, 2014)
"The objective of this systematic review was to evaluate the efficacy and safety of tranexamic acid in patients with spontaneous intracerebral hemorrhage."	5.12	Tranexamic Acid for Adult Patients with Spontaneous Intracerebral Hemorrhage: A Systematic Review with Meta-analysis. ( Ma, L; Song, J; Wang, X; You, C, 2021)
"Treatment with tranexamic acid could reduce rebleeding and hematoma expansion in cerebral hemorrhage without an increase in single ischemic adverse events, but it could increase the risk of combined ischemic events; however, the lack of improvement in mortality and the poor functional outcomes limit the value of clinical application."	5.01	Tranexamic Acid in Cerebral Hemorrhage: A Meta-Analysis and Systematic Review. ( Chen, X; He, Z; Hu, W; Song, Z; Xin, Y; Zhao, Y, 2019)
"Tranexamic acid might be beneficial for cerebral hemorrhage."	4.98	Influence of tranexamic acid on cerebral hemorrhage: A meta-analysis of randomized controlled trials. ( Huang, B; Xu, J; Xu, Q; Ye, R, 2018)
"prothrombin complex concentrate and fresh-frozen plasma effectively prevent hematoma growth in murine warfarin-associated intracerebral hemorrhage, whereas Factor VIIa was less effective."	3.77	Comparative effectiveness of hemostatic therapy in experimental warfarin-associated intracerebral hemorrhage. ( Heiland, S; Illanes, S; Schwarting, S; Veltkamp, R; Zhou, W, 2011)
"Data from the Tranexamic acid in IntraCerebral Hemorrhage-2 (TICH-2) randomized controlled trial were analyzed."	3.01	Predictors and Outcomes of Neurological Deterioration in Intracerebral Hemorrhage: Results from the TICH-2 Randomized Controlled Trial. ( Appleton, JP; Bath, PM; Bereczki, D; Cala, L; Ciccone, A; Dineen, R; England, TJ; Law, ZK; Mistri, AK; Ozturk, S; Sprigg, N, 2021)
"Rationale Acute intracerebral hemorrhage inflicts a high-economic and -health burden."	2.84	Tranexamic acid for acute intracerebral hemorrhage growth predicted by spot sign trial: Rationale and design. ( Li, N; Liu, D; Liu, L; Meng, X; Nie, X; Tan, Y; Wang, Y; Zhao, X, 2017)
"Spontaneous intracerebral hemorrhage (ICH) can be devastating, particularly if hematoma expansion (HE) occurs."	2.79	Tranexamic acid for spontaneous intracerebral hemorrhage: a randomized controlled pilot trial (ISRCTN50867461). ( Bath, PM; Dineen, RA; Kwong, Y; Renton, CJ; Sprigg, N, 2014)
"Cerebral amyloid angiopathy is a devastating cause of intracerebral hemorrhage for which there is no specific secondary stroke prevention treatment."	2.72	Cerebral Amyloid Angiopathy and the Fibrinolytic System: Is Plasmin a Therapeutic Target? ( Cloud, GC; Keragala, CB; Markus, HS; Medcalf, RL; Mutimer, CA; Werring, DJ, 2021)
"Tranexamic acid (TXA) is an antifibrinolytic agent, which has shown an effect on reducing blood loss in many diseases."	2.72	Tranexamic Acid Inhibits Hematoma Expansion in Intracerebral Hemorrhage and Traumatic Brain Injury. Does Blood Pressure Play a Potential Role? A Meta-Analysis from Randmized Controlled Trials. ( Chen, Z; Gao, B; Rong, X; Wang, Z; Xue, T; Yang, Y, 2021)
"Tranexamic acid shows some treatment efficacy for traumatic brain injury."	2.66	The efficacy of tranexamic acid for brain injury: A meta-analysis of randomized controlled trials. ( Chen, H; Chen, M, 2020)
"In 48 patients with a subarachnoid hemorrhage, levels of fibrin/fibrinogen degradation products (FDP's), total protein, and plasminogen were measured in the cerebrospinal fluid (CSF) between Days 9 and 15 after the bleed."	2.66	Source of fibrin/fibrinogen degradation products in the CSF after subarachnoid hemorrhage. ( Hijdra, A; Lindsay, KW; van Gijn, J; van Vliet, HH; Vermeulen, M, 1985)
"Primary intracerebral hemorrhage is the least treatable form of stroke and is associated with high mortality rates."	2.44	Epidemiological, clinical, and therapeutic aspects of primary intracerebral hemorrhage. ( Ciccone, A; Motto, C; Pozzi, M; Sterzi, R; Tiraboschi, P, 2008)
"Persistent intracerebral hemorrhage (ICH) is a major cause of death and disability after traumatic brain injury (TBI) for which no medical treatment is available."	1.42	Endogenous plasminogen activators mediate progressive intracerebral hemorrhage after traumatic brain injury in mice. ( Abdeen, S; Abramovitch, R; Abu Fanne, R; Basheer, M; Cines, DB; Higazi, AA; Higazi, M; Hijazi, N; Maraga, E; Yarovoi, S, 2015)
"Immediately after diagnosis of intracerebral hemorrhage on computed tomographic scan, 156 patients who were admitted within 24 hours of onset were treated with either a combination of PAF and BPC (PAF group) or a combination of RAF and BPC (RAF group)."	1.33	Rapid administration of antifibrinolytics and strict blood pressure control for intracerebral hemorrhage. ( Fujii, Y; Morita, K; Sorimachi, T; Tanaka, R, 2005)

Timeframe	Studies, this research(%)	All Research%
pre-1990	4 (7.55)	18.7374
1990's	2 (3.77)	18.2507
2000's	5 (9.43)	29.6817
2010's	20 (37.74)	24.3611
2020's	22 (41.51)	2.80

Trial	Phase	Enrollment	Study Type	Start Date	Status
STOP-AUST: The Spot Sign and Tranexamic Acid On Preventing ICH Growth - AUStralasia Trial.[NCT01702636]	Phase 2	100 participants (Actual)	Interventional	2012-12-31	Completed
TRACE STUDY: A Randomized Controlled Trial Using Tranexamic Acid in the Treatment of Subdural Hematoma[NCT05713630]	Phase 3	130 participants (Anticipated)	Interventional	2024-03-31	Not yet recruiting
A Randomized, Controlled, Double-blind, Multi-center Clinical Study of Shengdi Dahuang Decoction in the Treatment of Acute Hemorrhagic Stroke[NCT04200781]	Phase 4	464 participants (Anticipated)	Interventional	2019-09-01	Recruiting
Indian Trial of Tranexamic Acid in Spontaneous Intracerebral Haemorrhage[NCT05836831]	Phase 4	3,400 participants (Anticipated)	Interventional	2022-08-30	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Article	Year
Tranexamic Acid for Adult Patients with Spontaneous Intracerebral Hemorrhage: A Systematic Review with Meta-analysis. CNS drugs, 2021, Volume: 35, Issue:11 Topics: Adult; Antifibrinolytic Agents; Cerebral Hemorrhage; Hematoma; Humans; Randomized Controlled Trials	2021
The efficacy of tranexamic acid for brain injury: A meta-analysis of randomized controlled trials. The American journal of emergency medicine, 2020, Volume: 38, Issue:2 Topics: Antifibrinolytic Agents; Brain Injuries, Traumatic; Cerebral Hemorrhage; Humans; Randomized Controll	2020
Tranexamic Acid Inhibits Hematoma Expansion in Intracerebral Hemorrhage and Traumatic Brain Injury. Does Blood Pressure Play a Potential Role? A Meta-Analysis from Randmized Controlled Trials. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2021, Volume: 30, Issue:1 Topics: Antifibrinolytic Agents; Brain Hemorrhage, Traumatic; Cerebral Hemorrhage; Disease Progression; Hema	2021
Cerebral Amyloid Angiopathy and the Fibrinolytic System: Is Plasmin a Therapeutic Target? Stroke, 2021, Volume: 52, Issue:8 Topics: Amyloid beta-Peptides; Antibodies, Monoclonal; Antifibrinolytic Agents; Cerebral Amyloid Angiopathy;	2021
Tranexamic acid in intracerebral hemorrhage: a meta-analysis. The International journal of neuroscience, 2023, Volume: 133, Issue:6 Topics: Antifibrinolytic Agents; Cerebral Hemorrhage; Cohort Studies; Hematoma; Humans; Randomized Controlle	2023
Influence of tranexamic acid on cerebral hemorrhage: A meta-analysis of randomized controlled trials. Clinical neurology and neurosurgery, 2018, Volume: 171 Topics: Antifibrinolytic Agents; Cerebral Hemorrhage; Correlation of Data; Humans; Randomized Controlled Tri	2018
Intracerebral haemorrhage is hard to stop, and must be attacked before, during and after. BMJ evidence-based medicine, 2019, Volume: 24, Issue:5 Topics: Cerebral Hemorrhage; Humans; Stroke; Tranexamic Acid	2019
Tranexamic Acid in Cerebral Hemorrhage: A Meta-Analysis and Systematic Review. CNS drugs, 2019, Volume: 33, Issue:4 Topics: Antifibrinolytic Agents; Cerebral Hemorrhage; Humans; Stroke; Tranexamic Acid	2019
Reversal of oral anticoagulation in patients with acute intracerebral hemorrhage. Critical care (London, England), 2019, Jun-06, Volume: 23, Issue:1 Topics: Administration, Oral; Anticoagulants; Antidotes; Antithrombins; Blood Coagulation; Cerebral Hemorrha	2019
Epidemiological, clinical, and therapeutic aspects of primary intracerebral hemorrhage. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2008, Volume: 29 Suppl 2 Topics: Antifibrinolytic Agents; Cerebral Arteries; Cerebral Hemorrhage; Coagulants; Drug Administration Sch	2008
[The timing of surgical treatment for ruptured intracranial aneurysms--from the viewpoint of intentionally delayed operation (author's transl)]. Neurologia medico-chirurgica, 1981, Volume: 21, Issue:8 Topics: Cerebral Hemorrhage; Fibrinolysis; Hemostasis; Humans; Intracranial Aneurysm; Methods; Rupture, Spon	1981
Intraventricular hemorrhage: emphasis on prevention. Seminars in pediatric neurology, 1998, Volume: 5, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antifibrinolytic Agents; Blood Coagulation Disorders; Cereb	1998

Article	Year
Brief Consent Methods Enable Rapid Enrollment in Acute Stroke Trial: Results From the TICH-2 Randomized Controlled Trial. Stroke, 2022, Volume: 53, Issue:4 Topics: Cerebral Hemorrhage; Humans; Informed Consent; Logistic Models; Stroke; Tranexamic Acid; Treatment O	2022
Tranexamic acid for intracerebral haemorrhage within 2 hours of onset: protocol of a phase II randomised placebo-controlled double-blind multicentre trial. Stroke and vascular neurology, 2022, Volume: 7, Issue:2 Topics: Antifibrinolytic Agents; Cerebral Hemorrhage; Clinical Trials, Phase II as Topic; Hematoma; Humans;	2022
Effect of Tranexamic Acid Administration on Remote Cerebral Ischemic Lesions in Acute Spontaneous Intracerebral Hemorrhage: A Substudy of a Randomized Clinical Trial. JAMA neurology, 2022, 05-01, Volume: 79, Issue:5 Topics: Aged; Antifibrinolytic Agents; Cerebral Hemorrhage; Double-Blind Method; Female; Hematoma; Humans; I	2022
Tranexamic Acid for Intracerebral Hemorrhage in Patients on Non-Vitamin K Antagonist Oral Anticoagulants (TICH-NOAC): A Multicenter, Randomized, Placebo-Controlled, Phase 2 Trial. Stroke, 2023, Volume: 54, Issue:9 Topics: Administration, Oral; Aged, 80 and over; Anticoagulants; Antifibrinolytic Agents; Cerebral Hemorrhag	2023
Tranexamic acid in traumatic brain injury: an explanatory study nested within the CRASH-3 trial. European journal of trauma and emergency surgery : official publication of the European Trauma Society, 2021, Volume: 47, Issue:1 Topics: Adult; Antifibrinolytic Agents; Brain Injuries, Traumatic; Cerebral Hemorrhage; Female; Glasgow Coma	2021
Predictors and Outcomes of Neurological Deterioration in Intracerebral Hemorrhage: Results from the TICH-2 Randomized Controlled Trial. Translational stroke research, 2021, Volume: 12, Issue:2 Topics: Aged; Cerebral Hemorrhage; Hematoma; Humans; Logistic Models; Male; Tranexamic Acid	2021
Rationale and Design of a Randomized, Double-Blind Trial Evaluating the Efficacy of Tranexamic Acid on Hematoma Expansion and Peri-hematomal Edema in Patients with Spontaneous Intracerebral Hemorrhage within 4.5 h after Symptom Onset: The THE-ICH Trial Pr Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2020, Volume: 29, Issue:10 Topics: Antifibrinolytic Agents; Brain Edema; Cerebral Hemorrhage; China; Disease Progression; Double-Blind	2020
Tranexamic acid in patients with intracerebral haemorrhage (STOP-AUST): a multicentre, randomised, placebo-controlled, phase 2 trial. The Lancet. Neurology, 2020, Volume: 19, Issue:12 Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Cerebral Hemorrhage; Double-Blind Method; Female;	2020
Effect of Intravenous Tranexamic Acid on Intracerebral Brain Hemorrhage in Traumatic Brain Injury. Turkish neurosurgery, 2021, Volume: 31, Issue:2 Topics: Administration, Intravenous; Adolescent; Adult; Aged; Antifibrinolytic Agents; Brain Injuries, Traum	2021
Tranexamic acid for acute intracerebral haemorrhage growth based on imaging assessment (TRAIGE): a multicentre, randomised, placebo-controlled trial. Stroke and vascular neurology, 2021, Volume: 6, Issue:2 Topics: Adult; Aged; Antifibrinolytic Agents; Cerebral Hemorrhage; Female; Hematoma; Humans; Male; Middle Ag	2021
Tranexamic Acid for Prevention of Hematoma Expansion in Intracerebral Hemorrhage Patients With or Without Spot Sign. Stroke, 2021, Volume: 52, Issue:8 Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Cerebral Angiography; Cerebral Hemorrhage; Compute	2021
Tranexamic acid for acute intracerebral hemorrhage growth predicted by spot sign trial: Rationale and design. International journal of stroke : official journal of the International Stroke Society, 2017, Volume: 12, Issue:3 Topics: Antifibrinolytic Agents; Brain; Cerebral Hemorrhage; Disease Progression; Humans; Research Design; T	2017
Statistical analysis plan for the 'Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage' (TICH-2) trial. Trials, 2017, Dec-20, Volume: 18, Issue:1 Topics: Antifibrinolytic Agents; Cerebral Hemorrhage; Clinical Protocols; Data Interpretation, Statistical;	2017
Does tranexamic acid lead to changes in MRI measures of brain tissue health in patients with spontaneous intracerebral haemorrhage? Protocol for a MRI substudy nested within the double-blind randomised controlled TICH-2 trial. BMJ open, 2018, 02-03, Volume: 8, Issue:2 Topics: Antifibrinolytic Agents; Brain; Cerebral Hemorrhage; Double-Blind Method; Humans; International Coop	2018
Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial. Lancet (London, England), 2018, 05-26, Volume: 391, Issue:10135 Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Cerebral Hemorrhage; Double-	2018
Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial. Lancet (London, England), 2018, 05-26, Volume: 391, Issue:10135 Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Cerebral Hemorrhage; Double-	2018
Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial. Lancet (London, England), 2018, 05-26, Volume: 391, Issue:10135 Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Cerebral Hemorrhage; Double-	2018
Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial. Lancet (London, England), 2018, 05-26, Volume: 391, Issue:10135 Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Cerebral Hemorrhage; Double-	2018
Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial. Lancet (London, England), 2018, 05-26, Volume: 391, Issue:10135 Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Cerebral Hemorrhage; Double-	2018
Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial. Lancet (London, England), 2018, 05-26, Volume: 391, Issue:10135 Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Cerebral Hemorrhage; Double-	2018
Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial. Lancet (London, England), 2018, 05-26, Volume: 391, Issue:10135 Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Cerebral Hemorrhage; Double-	2018
Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial. Lancet (London, England), 2018, 05-26, Volume: 391, Issue:10135 Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Cerebral Hemorrhage; Double-	2018
Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial. Lancet (London, England), 2018, 05-26, Volume: 391, Issue:10135 Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Cerebral Hemorrhage; Double-	2018
Prevention of haematoma progression by tranexamic acid in intracerebral haemorrhage patients with and without spot sign on admission scan: a statistical analysis plan of a pre-specified sub-study of the TICH-2 trial. BMC research notes, 2018, Jun-13, Volume: 11, Issue:1 Topics: Antifibrinolytic Agents; Cerebral Hemorrhage; Data Interpretation, Statistical; Disease Progression;	2018
Tranexamic acid to improve functional status in adults with spontaneous intracerebral haemorrhage: the TICH-2 RCT. Health technology assessment (Winchester, England), 2019, Volume: 23, Issue:35 Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Cerebral Hemorrhage;	2019
The spot sign and tranexamic acid on preventing ICH growth--AUStralasia Trial (STOP-AUST): protocol of a phase II randomized, placebo-controlled, double-blind, multicenter trial. International journal of stroke : official journal of the International Stroke Society, 2014, Volume: 9, Issue:4 Topics: Adult; Aged; Antifibrinolytic Agents; Australia; Cerebral Angiography; Cerebral Hemorrhage; Contrast	2014
The spot sign and tranexamic acid on preventing ICH growth--AUStralasia Trial (STOP-AUST): protocol of a phase II randomized, placebo-controlled, double-blind, multicenter trial. International journal of stroke : official journal of the International Stroke Society, 2014, Volume: 9, Issue:4 Topics: Adult; Aged; Antifibrinolytic Agents; Australia; Cerebral Angiography; Cerebral Hemorrhage; Contrast	2014
The spot sign and tranexamic acid on preventing ICH growth--AUStralasia Trial (STOP-AUST): protocol of a phase II randomized, placebo-controlled, double-blind, multicenter trial. International journal of stroke : official journal of the International Stroke Society, 2014, Volume: 9, Issue:4 Topics: Adult; Aged; Antifibrinolytic Agents; Australia; Cerebral Angiography; Cerebral Hemorrhage; Contrast	2014
The spot sign and tranexamic acid on preventing ICH growth--AUStralasia Trial (STOP-AUST): protocol of a phase II randomized, placebo-controlled, double-blind, multicenter trial. International journal of stroke : official journal of the International Stroke Society, 2014, Volume: 9, Issue:4 Topics: Adult; Aged; Antifibrinolytic Agents; Australia; Cerebral Angiography; Cerebral Hemorrhage; Contrast	2014
Tranexamic acid for spontaneous intracerebral hemorrhage: a randomized controlled pilot trial (ISRCTN50867461). Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2014, Volume: 23, Issue:6 Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Cerebral Hemorrhage; Double-Blind Method; Female;	2014
Intravenous tranexamic acid for hyperacute primary intracerebral hemorrhage: Protocol for a randomized, placebo-controlled trial. International journal of stroke : official journal of the International Stroke Society, 2016, Volume: 11, Issue:6 Topics: Administration, Intravenous; Affect; Antifibrinolytic Agents; Cerebral Hemorrhage; Cognition; Disabi	2016
Tranexamic acid in the prevention of periventricular haemorrhage. Archives of disease in childhood, 1984, Volume: 59, Issue:8 Topics: Cerebral Hemorrhage; Cerebral Ventricles; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Dou	1984
Source of fibrin/fibrinogen degradation products in the CSF after subarachnoid hemorrhage. Journal of neurosurgery, 1985, Volume: 63, Issue:4 Topics: Blood Physiological Phenomena; Cerebral Hemorrhage; Cerebrospinal Fluid; Clinical Trials as Topic; D	1985

Article	Year
Tranexamic Acid and Diffusion-Weighted Imaging Lesions After Intracerebral Hemorrhage. JAMA neurology, 2022, 05-01, Volume: 79, Issue:5 Topics: Antifibrinolytic Agents; Cerebral Hemorrhage; Diffusion Magnetic Resonance Imaging; Humans; Tranexam	2022
[Focus on neurosurgery : Intensive care studies from 2018-2019]. Der Anaesthesist, 2020, Volume: 69, Issue:3 Topics: Cerebral Hemorrhage; Critical Care; Humans; Neurosurgery; Neurosurgical Procedures; Tranexamic Acid	2020
No hyperfibrinolysis following subarachnoid or intracerebral haemorrhage: a prospective cohort study. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2019, Volume: 30, Issue:7 Topics: Adult; Aged; Blood Coagulation Factors; Case-Control Studies; Cerebral Hemorrhage; Female; Fibrin Cl	2019
Noncontrast Computed Tomography Signs as Predictors of Hematoma Expansion, Clinical Outcome, and Response to Tranexamic Acid in Acute Intracerebral Hemorrhage. Stroke, 2020, Volume: 51, Issue:1 Topics: Aged; Cerebral Hemorrhage; Cohort Studies; Disease Progression; Female; Hematoma; Humans; Logistic M	2020
The STOP-AUST trial: a test for the spot sign in intracerebral haemorrhage. The Lancet. Neurology, 2020, Volume: 19, Issue:12 Topics: Cerebral Angiography; Cerebral Hemorrhage; Humans; Patients; Tranexamic Acid	2020
Tranexamic acid and traumatic brain injuries. JAAPA : official journal of the American Academy of Physician Assistants, 2020, Volume: 33, Issue:12 Topics: Antifibrinolytic Agents; Brain Injuries, Traumatic; Cerebral Hemorrhage; Female; Humans; Male; Rando	2020
Outcomes in Antiplatelet-Associated Intracerebral Hemorrhage in the TICH-2 Randomized Controlled Trial. Journal of the American Heart Association, 2021, Volume: 10, Issue:5 Topics: Aged; Antifibrinolytic Agents; Cerebral Hemorrhage; Disease Progression; Dose-Response Relationship,	2021
Intracerebral hemorrhage research, no longer the bridesmaid to ischemic stroke. International journal of stroke : official journal of the International Stroke Society, 2019, Volume: 14, Issue:3 Topics: Antifibrinolytic Agents; Cerebral Hemorrhage; Clinical Trials as Topic; Hemostasis; Humans; Stroke;	2019
Just the facts: Management of life-threatening bleeding with oral anticoagulant use in the emergency department. CJEM, 2019, Volume: 21, Issue:4 Topics: Administration, Oral; Algorithms; Antibodies, Monoclonal, Humanized; Anticoagulants; Antifibrinolyti	2019
Endogenous plasminogen activators mediate progressive intracerebral hemorrhage after traumatic brain injury in mice. Blood, 2015, Apr-16, Volume: 125, Issue:16 Topics: Animals; Antifibrinolytic Agents; Brain; Brain Injuries; Cerebral Hemorrhage; Fibrin; Fibrinolysis;	2015
Comparative effectiveness of hemostatic therapy in experimental warfarin-associated intracerebral hemorrhage. Stroke, 2011, Volume: 42, Issue:1 Topics: Animals; Anticoagulants; Blood Coagulation Factors; Cerebral Hemorrhage; Collagenases; Disease Model	2011
Treatment of intracerebral hemorrhage with tranexamic acid after thrombolysis with tissue plasminogen activator. Neurocritical care, 2012, Volume: 17, Issue:1 Topics: Antifibrinolytic Agents; Cerebral Hemorrhage; Drug Interactions; Fatal Outcome; Fibrinolytic Agents;	2012
Treatment of spontaneous intracerebral haemorrhage in Glanzmann's thrombasthenia. Haemophilia : the official journal of the World Federation of Hemophilia, 2012, Volume: 18, Issue:5 Topics: Antifibrinolytic Agents; Cerebral Hemorrhage; Factor VIIa; Female; Humans; Magnetic Resonance Imagin	2012
Successful treatment of acute promyelocytic leukaemia during pregnancy. Clinical and laboratory haematology, 2002, Volume: 24, Issue:5 Topics: Adolescent; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Cerebral Hemorrhage; Ce	2002
Rapid administration of antifibrinolytics and strict blood pressure control for intracerebral hemorrhage. Neurosurgery, 2005, Volume: 57, Issue:5 Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Blood Pressure; Case-Control Studies; Cerebral Hemo	2005
Rapid administration of antifibrinolytics and strict blood pressure control for intracerebral hemorrhage. Neurosurgery, 2006, Volume: 58, Issue:5 Topics: Antifibrinolytic Agents; Blood Pressure; Cerebral Hemorrhage; Humans; Time Factors; Tranexamic Acid	2006
Predictors of hematoma enlargement in patients with intracerebral hemorrhage treated with rapid administration of antifibrinolytic agents and strict blood pressure control. Journal of neurosurgery, 2007, Volume: 106, Issue:2 Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Antihypertensive Agents; Cerebral Hemorrhage; Drug	2007
What about medical therapy alone? JAMA, 1978, Nov-10, Volume: 240, Issue:20 Topics: Antifibrinolytic Agents; Cerebral Hemorrhage; Cyclohexanecarboxylic Acids; Humans; Intracranial Aneu	1978
Differential effects of aprotinin and tranexamic acid on cerebral bleeding and cutaneous bleeding time during rt-PA infusion. Thrombosis research, 1991, Jan-15, Volume: 61, Issue:2 Topics: Animals; Aprotinin; Bleeding Time; Cerebral Hemorrhage; Female; Infusions, Intravenous; Rats; Rats,	1991

tranexamic acid and Brain Hemorrhage, Cerebral

Research Excerpts

Research

Studies (53)

Authors

Clinical Trials (4)

Trial Overview

Reviews

Trials

Other Studies

Authors	Studies
Wang, X	1
Ma, L	1
Song, J	1
You, C	1
Law, ZK	9
Appleton, JP	5
Scutt, P	5
Roberts, I	7
Al-Shahi Salman, R	7
England, TJ	7
Werring, DJ	6
Robinson, T	3
Krishnan, K	5
Dineen, RA	9
Laska, AC	5
Lyrer, PA	2
Egea-Guerrero, JJ	5
Karlinski, M	3
Christensen, H	7
Roffe, C	6
Bereczki, D	7
Ozturk, S	7
Thanabalan, J	4
Collins, R	5
Beridze, M	4
Ciccone, A	7
Duley, L	4
Shone, A	1
Bath, PM	12
Sprigg, N	14
Yassi, N	3
Zhao, H	1
Churilov, L	3
Campbell, BCV	2
Wu, T	1
Ma, H	2
Cheung, A	1
Kleinig, T	3
Brown, H	1
Choi, P	1
Jeng, JS	2
Ranta, A	1
Wang, HK	1
Cloud, GC	3
Grimley, R	1
Shah, D	2
Spratt, N	1
Cho, DY	2
Mahawish, K	1
Sanders, L	1
Worthington, J	1
Clissold, B	1
Meretoja, A	3
Yogendrakumar, V	1
Ton, MD	1
Dang, DP	1
Phuong, NTM	1
Nguyen, HT	1
Hsu, CY	2
Sharma, G	2
Mitchell, PJ	1
Yan, B	3
Parsons, MW	3
Levi, C	3
Donnan, GA	3
Davis, SM	3
Oh, SE	1
Murthy, SB	1
Pszczolkowski, S	3
Woodhouse, LJ	1
Gallagher, R	1
Swienton, D	1
Casado, AM	1
Morgan, PS	2
Polymeris, AA	1
Karwacki, GM	1
Siepen, BM	1
Schaedelin, S	1
Tsakiris, DA	1
Stippich, C	1
Guzman, R	1
Nickel, CH	1
Kägi, G	1
Vehoff, J	1
Barinka, F	1
Thilemann, S	1
Maurer, M	1
Wagner, B	1
Traenka, C	1
Gensicke, H	1
De Marchis, GM	1
Bonati, LH	1
Fischer, U	1
Z'Graggen, WJ	1
Nedeltchev, K	1
Wegener, S	1
Baumgartner, P	1
Engelter, ST	1
Seiffge, DJ	1
Peters, N	3
Beynon, C	1
Bernhard, M	1
Brenner, T	1
Dietrich, M	1
Nusshag, C	1
Weigand, MA	1
Reuß, CJ	1
Michalski, D	1
Jungk, C	1
Lauridsen, SV	1
Hvas, CL	1
Sandgaard, E	1
Gyldenholm, T	1
Tønnesen, EK	1
Hvas, AM	1
Chen, H	1
Chen, M	1
Ali, A	1
Bischoff, A	1
Woodhouse, L	2
Cala, LA	1
Ovesen, C	4
Dineen, R	4
Cala, L	1
Mistri, AK	1
Jiang, C	1
Wang, J	2
Zhang, J	1
Wu, TY	1
Sibolt, G	1
Spratt, NJ	2
Thijs, V	1
Wijeratne, T	2
Phan, T	1
Bladin, C	2
Moey, A	1
Aviv, RI	2
Barras, CD	1
Mitchell, P	2
Tiainen, M	1
Curtze, S	1
Strbian, D	1
Tang, SC	1
Harvey, J	1
Gao, B	1
Xue, T	1
Rong, X	1
Yang, Y	1
Wang, Z	2
Chen, Z	1
Sanford, K	1
Garcia, S	1
Desborough, M	1
Safari, H	1
Farrahi, P	1
Rasras, S	1
Marandi, HJ	1
Zeinali, M	1
Liu, J	1
Nie, X	2
Gu, H	1
Zhou, Q	1
Sun, H	1
Tan, Y	2
Liu, D	2
Zheng, L	1
Zhao, J	1
Wang, Y	3
Cao, Y	1
Zhu, H	1
Zhang, Y	1
Yi, L	1
Pu, Y	1
Wen, M	1
Yang, Z	1
Sun, S	1
Wang, W	1
Zhao, X	2
Liu, L	2
Jakobsen, JC	2
Gluud, C	2
Steiner, T	2
Law, Z	3
Flaherty, K	6
Christensen, LM	1
Overgaard, K	1
Rasmussen, RS	1
Mutimer, CA	1
Keragala, CB	1
Markus, HS	1
Medcalf, RL	1
Yu, Z	1
Ling, L	1
Meng, X	1
Li, N	1
Pocock, S	2
England, T	2
Czlonkowska, A	2
Pocock, SJ	2
Robinson, TG	2
Seiffge, D	2
Werring, D	3
Whynes, D	3
Huang, B	1
Xu, Q	1
Ye, R	1
Xu, J	1
Tirschwell, DL	1
Hu, W	1
Xin, Y	1
Chen, X	1
Song, Z	1
He, Z	1
Zhao, Y	1
Donnan, G	1
Ho, ML	1
Carrier, M	1
Kuramatsu, JB	1
Sembill, JA	1
Huttner, HB	1
Campbell, BC	1
Barras, C	1
Nandurkar, H	1
Jannes, J	1
Sturm, J	1
Rupasinghe, J	1
Zavala, J	1
Lee, A	1
Markus, R	1
Delcourt, C	1
Mahant, N	1
Anderson, CS	1
Renton, CJ	1
Kwong, Y	1
Hijazi, N	1
Abu Fanne, R	1
Abramovitch, R	1
Yarovoi, S	1
Higazi, M	1
Abdeen, S	1
Basheer, M	1
Maraga, E	1
Cines, DB	1
Higazi, AA	1
Robson, K	1
Bath, P	1
Beredzie, M	1
Pozzi, M	1
Motto, C	1
Tiraboschi, P	1
Sterzi, R	1
Illanes, S	1
Zhou, W	1
Schwarting, S	1
Heiland, S	1
Veltkamp, R	1
French, KF	1
White, J	1
Hoesch, RE	1
Vigren, P	1
Ström, JO	1
Petrini, P	1
Callander, M	1
Theodorsson, A	1
Carradice, D	1
Austin, N	1
Bayston, K	1
Ganly, PS	1
Sorimachi, T	2
Fujii, Y	2
Morita, K	2
Tanaka, R	2
Fodstad, H	1
Aiba, T	1
Hensey, OJ	1
Morgan, ME	1
Cooke, RW	1
Hill, A	1
Check, W	1
de Bono, DP	1
Pringle, S	1
Underwood, I	1
Vermeulen, M	1
van Vliet, HH	1
Lindsay, KW	1
Hijdra, A	1
van Gijn, J	1